<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495274</url>
  </required_header>
  <id_info>
    <org_study_id>OXS105205</org_study_id>
    <nct_id>NCT00495274</nct_id>
  </id_info>
  <brief_title>Bioequivalence and Food Effect Study in Healthy Volunteers</brief_title>
  <official_title>A Single-centre, Open-label, Randomized, Single-dose, 6-way Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of 6 Different Formulations of SB-649868 30 mg (Part A) and the Effect of Food on the Selected Formulation of SB-649868 Pharmacokinetic (Part B) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select the formulation with the optimal pharmacokinetic
      profile for an hypnotic drug to further develop in the market.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-centre, open-label, randomized, single-dose, 6-way crossover study to investigate
      the pharmacokinetics, safety and tolerability of 6 different formulations of SB-649868 30 mg
      (Part A) and the effect of food on the selected formulation of SB-649868 pharmacokinetic
      (Part B) in healthy male volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2007</start_date>
  <completion_date type="Actual">September 26, 2007</completion_date>
  <primary_completion_date type="Actual">September 26, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>-Part A: SB-649868 levels of 6 formulation predose, 0.5, 1, 1.5, 2,3,4,5,6,8,12 and 24hours post-dose</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2,3,4,5,6,8,12 and 24hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>-Part B: SB-649868 levels of selected formulation after food at the same timepoints as in Part A</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2,3,4,5,6,8,12 and 24hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-AE, Lab values and cardiovascular monitoring throughout study participation</measure>
    <time_frame>throughout study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Romberg heel-to-toe test at discharge</measure>
    <time_frame>at discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Cognitive functions predose, 0.5, 1, 2, 4, 6 hours post-dose</measure>
    <time_frame>predose, 0.5, 1, 2, 4, 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic endpoint: Bond Lader Visual Analogue Scale (VAS) score</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 4, 6 hours post-dose on Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>Healthy male subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A each subject will participate in six sessions and will be administered, in randomized order, single doses of five new formulations (formulation B, C, D, E and F) of SB-649868 30 milligrams (mg), in fasted state and a single dose of the original formulation (formulation A), after a standard Food and Drug Administration (FDA) High-Fat breakfast. All dosing sessions will be separated by a washout session of at least 5 ± 2 days after each dose. In Part B a single dose of the selected SB-649868 30 mg formulation will be administered after a standard FDA High-Fat breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation A</intervention_name>
    <description>Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
    <other_name>SB-649868</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation B</intervention_name>
    <description>Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation C</intervention_name>
    <description>Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation D</intervention_name>
    <description>Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation E</intervention_name>
    <description>Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation F</intervention_name>
    <description>Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation G</intervention_name>
    <description>Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast</description>
    <arm_group_label>Healthy male subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy adult male subjects aged between 18 and 65 years of age inclusive.

          -  Body weight and BMI within the protocol ranges.

          -  Healthy as determined by a responsible physician, based on a medical evaluation
             including history, physical examination, laboratory tests, cardiac monitoring.

          -  Circulating levels of LH, FSH and testosterone within the normal reference range.

          -  Signed and dated written informed consent.

          -  The subject is able to understand and comply with protocol requirements, instructions
             and protocol-stated restrictions.

        Exclusion criteria:

          -  Positive pre-study urine drug screen and alcohol breath test.

          -  Positive pre-study Hepatitis B surface antigen, Hepatitis C antibody, or HIV ½ result.

          -  Abuse of alcohol as per protocol criteria.

          -  Consumption of prohibited food and drink as per protocol.

          -  Subject who is not prepared to eat the standard meals provided by the site.

          -  Use of prescription or non-prescription drugs 1 or 2 weeks before the first dose of
             study medication.

          -  Where participation in study would result in donation of blood in excess of 500mL
             within a 56 day period.

          -  History or presence of allergy to the study drug or drugs of this class, or a history
             of other allergy.

          -  Smoking history in the last three months as per protocol.

          -  An unwillingness of male subjects to follow contraception methods as per protocol.

          -  History or presence of significant psychiatric, respiratory or gastrointestinal
             illnesses, hepatic or renal diseases or other condition known to interfere with the
             absorption, distribution, metabolism or excretion of drugs.

          -  The subject is unable or unwilling to abstain from strenuous physical activity in the
             48 hours before screening and in the 48 hours before and the 48 hours after the
             treatment period.

          -  Current or previous (within 6 months) participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/OXS105205?search=study&amp;search_terms=OXS105205#rs</url>
    <description>Results for study OXS105205 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2007</study_first_submitted>
  <study_first_submitted_qc>June 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalent</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>Reference formulation</keyword>
  <keyword>5 new formulation</keyword>
  <keyword>Food effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

